What question did this study set out to answer?

This research aims to develop selective STING-activating polysaccharides to enhance cancer therapy by targeting diverse cell types.

Cell Selective STING‐Activating Polysaccharide Immunomodulators for Cancer Therapy

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates selective STING activation's antitumor efficacy in tumor models, highlighting immune response reprogramming.

This research aims to develop selective STING-activating polysaccharides to enhance cancer therapy by targeting diverse cell types.
Engineered selective STING-activating polysaccharide immunomodulators (SSAPIs) using dextran as a nanocarrier.
Conducted in vitro experiments to test STING activation efficiency across tumor cells, macrophages, and dendritic cells.
Utilized B16F10 and CT26 tumor-bearing mouse models to evaluate antitumor efficacy of SSAPI variants.
DSSX demonstrated superior antitumor efficacy with six out of eight complete tumor remissions.
Enhanced STING activation was observed in macrophages with the DESX linker.
Broad immune responses were induced across diverse cell populations to reprogram the tumor microenvironment.

Zhu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark